BlossomHill Therapeutics advances pan-KRAS inhibitor BH-501284 toward Q1 2027 IND filing
The company said preclinical data on BH-501284 were presented at the AACR pancreatic cancer conference Sept. 25-28, 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.